Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Moody Longevity Trial: Tirzepatide to Slow Biological Aging

Authors not listed

The University of Texas Medical Branch, Galveston · 2026

Abstract

This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Anonymous. (2026). The Moody Longevity Trial: Tirzepatide to Slow Biological Aging. <em>The University of Texas Medical Branch, Galveston</em>. https://clinicaltrials.gov/study/NCT07220473
Vancouver
Anonymous. The Moody Longevity Trial: Tirzepatide to Slow Biological Aging. The University of Texas Medical Branch, Galveston. 2026.
BibTeX
@misc{anon2026TheMoo, title = {The Moody Longevity Trial: Tirzepatide to Slow Biological Aging}, author = {Anonymous}, journal = {The University of Texas Medical Branch, Galveston}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings